Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome

Blood

Volumn 124, Issue 6, 2014, Pages 873-881

  Shenoy, Niraj ^a   Vallumsetla, Nishanth ^a   Rachmilewitz, Eliezer ^b   Verma, Amit ^a   Ginzburg, Yelena ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WOLFSON MEDICAL CENTER   (Israel)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; HEPCIDIN; IRON; IRON CHELATING AGENT;

DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROCYTE TRANSFUSION; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ADVERSE EFFECTS; BIOLOGICAL MODEL; BLOOD; CHELATION THERAPY; COMPLICATION; ERYTHROCYTE; METABOLISM; MYELODYSPLASTIC SYNDROMES; RISK FACTOR;

CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; ERYTHROPOIESIS; HEPCIDINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; RISK FACTORS;

EID: 84905748509     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-563221     Document Type: Review

References (105)

1. Hellstrom-Lindberg E. Management of anemia associated with myelodysplastic syndrome. Semin Hematol. 2005;42(2 suppl 1):S10-S13. (Pubitemid 40410478)
2. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program). 2002: 136-161.
3. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25(23):3503-3510. (Pubitemid 47315575)
4. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603. (Pubitemid 46291823)
5. Delaby C, Pilard N, Puy H, Canonne-Hergaux F. Sequential regulation of ferroportin expression after erythrophagocytosis in murine macrophages: early mRNA induction by haem, followed by iron-dependent protein expression. Biochem J. 2008;411(1):123-131. (Pubitemid 351482354)
6. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275(26): 19906-19912. (Pubitemid 30441595)
7. McKie AT, Marciani P, Rolfs A, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell. 2000;5(2):299-309. (Pubitemid 30628088)
8. Huang Y, Liu DP, Wu L, et al. Proper developmental control of human globin genes reproduced by transgenic mice containing a 160-kb BAC carrying the human beta-globin locus. Blood Cells Mol Dis. 2000;26(6):598-610. (Pubitemid 32181903)
9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093. (Pubitemid 40007660)
10. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62: 347-360.
11. von Bonsdorff L, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J. Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies. Clin Chem. 2002;48(2):307-314. (Pubitemid 34107268)
12. Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84(1):29-33.
13. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277-287. (Pubitemid 40298370)
14. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in ironoverloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood. 2004;104(5): 1504-1510. (Pubitemid 39166531)
15. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica. 2010;95(8): 1433-1434.
16. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001;38(4):360-366. (Pubitemid 32995605)
17. Hershko CM, Link GM, Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Hematol Rep. 2005;4(2):110-116.
18. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
19. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101(1):91-96. (Pubitemid 36025892)
20. Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2 in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007;138(5): 587-593. (Pubitemid 47206717)
21. Konen E, Ghoti H, Goitein O, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol. 2007;82(11):1013-1016. (Pubitemid 350004394)
22. Di Tucci AA, Matta G, Deplano S, et al. Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93(9):1385-1388.
23. Roy NB, Myerson S, Schuh AH, et al. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes. Br J Haematol. 2011;154(4):521-524.
24. Leitch HA. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments. Drugs. 2011;71(2):155-177.
25. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006; 108(12):3730-3735. (Pubitemid 44864551)
26. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012;122(12):4635-4644.
27. Finch C. Regulators of iron balance in humans. Blood. 1994;84(6):1697-1702. (Pubitemid 24286117)
28. Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010;17(3):184-190.
29. Casanovas G, Vujic Spasic M, Casu C, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica. 2013; 98(3):444-447.
30. Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS ONE. 2011; 6(8):e23109.
31. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism [published online ahead of print June 1, 2014]. Nat Genet.
32. Qin Y, Liu H, Ruan S, Cai YF, You XF, Song GQ. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance]. Zhonghua Xue Ye Xue Za Zhi. 2011;32(11):758-761.
33. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007; 109(11):5027-5035. (Pubitemid 46827803)
34. Kearney SL, Nemeth E, Neufeld EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer. 2007;48(1):57-63. (Pubitemid 44871594)
35. Ohashi H, Arita K, Suzuki Y, et al. Iron chelation therapy for a case of transfusion-independent MDS-RARS with significant iron overload. Int J Hematol. 2013;97(1):151-153.
36. Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012;120(16):3173-3186.
37. Ambaglio I, Malcovati L, Papaemmanuil E, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica. 2013;98(3):420-423.
38. Malcovati L, Papaemmanuil E, Bowen DT, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-6246.
39. Gattermann N. SF3B1 and the riddle of the ring sideroblast. Blood. 2012;120(16):3167-3168.
40. Nearman ZP, Szpurka H, Serio B, et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol. 2007;82(12):1076-1079. (Pubitemid 350209849)
41. Valent P, Krieger O, Stauder R, et al. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest. 2008;38(3):143-149. (Pubitemid 351197091)
42. Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010;50(7):1568-1570.
43. Badawi MA, Vickars LM, Chase JM, Leitch HA. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol. 2010; 2010:164045.
44. Taoka K, Kumano K, Nakamura F, et al. The effect of iron overload and chelation on erythroid differentiation. Int J Hematol. 2012;95(2): 149-159.
45. Fibach E, Rachmilewitz EA. Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS. Leuk Res. 2012;36(8):962-963.
46. Pan Z, Voehringer DW, Meyn RE. Analysis of redox regulation of cytochrome c-induced apoptosis in a cell-free system. Cell Death Differ. 1999;6(7):683-688. (Pubitemid 29366658)
47. Hartmann J, Braulke F, Sinzig U, et al. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk Res. 2013; 37(3):327-332.
48. Camaschella C, Campanella A, De Falco L, et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood. 2007;110(4):1353-1358. (Pubitemid 47281436)
49. Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010;16(2):177-182.
50. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in b-thalassemic mice. J Clin Invest. 2010;120(12):4466-4477.
51. Nai A, Pagani A, Mandelli G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of b-thalassemia. Blood. 2012;119(21): 5021-5029.
52. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and b-thalassemia in mice. J Clin Invest. 2013; 123(4):1531-1541.
53. Schmidt PJ, Toudjarska I, Sendamarai AK, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine b-thalassemia intermedia. Blood. 2013;121(7): 1200-1208.
54. Dussiot MMT, Fricot A, Chartier C, et al. The activin receptor IIa ligand trap Sotatercept corrects ineffective erythropoiesis in betathalassemia. Nat Med. 2014;20(4):398-407.
55. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-b superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4): 408-414.
56. Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008;112(8): 3434-3443.
57. Zhou L, McMahon C, Bhagat T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011;71(3):955-963.
58. Kikuchi S, Kobune M, Iyama S, et al. Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome. Int J Hematol. 2012;95(5):527-534.
59. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112: Abstract 640.
60. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology (Am Soc Hematol Educ Program). 2009: 215-221.
61. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin. 2009;33(suppl 1):S46-S57.
62. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995; 89(4):757-761.
63. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110(4):971-977.
64. Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol. 2004; 126(5):736-742. (Pubitemid 39221312)
65. Cortelezzi A, Cattaneo C, Cristiani S, et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1(3):153-158.
66. Breuer W, Shvartsman M, Cabantchik ZI. Intracellular labile iron. Int J Biochem Cell Biol. 2008;40(3):350-354. (Pubitemid 351241220)
67. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7): 2670-2677. (Pubitemid 37193611)
68. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000; 355(9220):2051-2052. (Pubitemid 30339248)
69. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006;91(9): 1187-1192. (Pubitemid 44408428)
70. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23): 2171-2179. (Pubitemid 33139463)
71. Pennell DJ. T2 magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci. 2005;1054:373-378. (Pubitemid 43031044)
72. Armand P, Sainvil MM, Kim HT, et al. Pretransplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013;48(1):146-147.
73. Takatoku M, Uchiyama T, Okamoto S, et al; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78(6):487-494. (Pubitemid 46753591)
74. Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol. 2008;83(8): 611-613.
75. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res. 2007;31(suppl 3):S7-S9. (Pubitemid 350137501)
76. Rose C, Brechignac S, Vassilief D, et al; GFM (Groupe Francophone des Myelodysplasies). Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res. 2010;34(7):864-870.
77. Metzgeroth G, Dinter D, Schultheis B, et al. Deferasirox in MDS patients with transfusioncaused iron overload-A phase-II study. Ann Hematol. 2009;88(4):301-310.
78. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2): 168-176.
79. Gattermann N, Finelli C, Porta MD, et al; EPIC study investigators. Deferasirox in ironoverloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010;34(9): 1143-1150.
80. List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30(17):2134-2139.
81. Ghoti H, Fibach E, Westerman M, Gordana O, Ganz T, Rachmilewitz EA. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. Br J Haematol. 2011;153(1):118-120.
82. Al-Rousan RM, Paturi S, Laurino JP, et al. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. Am J Hematol. 2009;84(9):565-570.
83. Cappellini MD, Porter J, El-Beshlawy A, et al; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
84. Angelucci E, Santini V, Di Tucci A, et al. Deferasirox chelation therapy in transfusiondependent MDS patients: final report from the Gimema MDS0306 prospective trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2012; 120: Abstract 425.
85. Cancado R, Olivato MC, Bruniera P, et al. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients. Acta Haematol. 2012;128(2):113-118.
86. Steensma DP. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. Curr Hematol Malig Rep. 2011;6(2):136-144.
87. Jaeger M, Aul C, Sohngen D, et al. Iron overload in polytransfused patients with MDS. Use of L1 for oral iron chelation. Drugs Today (Barc). 1992; 28:143-147.
88. al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol. 1994;53(5):298-301.
89. Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leuk Res. 2013; 37(12):1612-1615.
90. Cermak J, Jonasova A, Vondrakova J, et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin. 2011; 35(3):217-227.
91. Bennett JM; MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83(11): 858-861.
92. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol. 2008;88(1):24-29.
93. Zipperer E, Pelz D, Nachtkamp K, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94(5):729-732.
94. Oliva EN, Dimitrov BD, Benedetto F, D'Angelo A, Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res. 2005;29(10):1217-1219. (Pubitemid 41169239)
95. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin 1 granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-1046. (Pubitemid 36411563)
96. Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008;142(3):379-393. (Pubitemid 351962168)
97. Novotna B, Bagryantseva Y, Siskova M, Neuwirtova R. Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. Leuk Res. 2009; 33(2):340-343.
98. Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010; 207(4):731-750.
99. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94(2):288-299. (Pubitemid 26247987)
100. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70-74.
101. Capalbo S, Spinosa G, Franzese MG, Palumbo G. Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol. 2009;121(1): 19-20.
102. Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97(9):1364-1371.
103. Improta S, Villa MR, Volpe A, et al. Transfusiondependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up. Oncol Lett. 2013;6(6):1774-1778.
104. Saigo K, Kono M, Takagi Y, et al. Deferasirox reduces oxidative stress in patients with transfusion dependency. J Clin Med Res. 2013; 5(1):57-60.
105. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011; 364(2):146-156.